About MediWound Ltd.
https://www.mediwound.comMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
CEO
Ofer Gonen
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-12-20 | Reverse | 1:7 |
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
INVESTOR AB
Shares:872.09K
Value:$14.86M
YELIN LAPIDOT HOLDINGS MANAGEMENT LTD.
Shares:809.95K
Value:$13.8M
ROSALIND ADVISORS, INC.
Shares:749.05K
Value:$12.76M
Summary
Showing Top 3 of 86
About MediWound Ltd.
https://www.mediwound.comMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.43M ▼ | $7.42M ▲ | $-2.65M ▲ | -48.85% ▲ | $-0.24 ▲ | $-2.18M ▲ |
| Q2-2025 | $5.71M ▲ | $7.06M ▲ | $-13.32M ▼ | -233.32% ▼ | $-1.23 ▼ | $-4.89M ▼ |
| Q1-2025 | $3.96M ▼ | $5.96M ▼ | $-726K ▲ | -18.36% ▲ | $-0.07 ▲ | $-363K ▲ |
| Q4-2024 | $5.84M ▲ | $6.99M ▲ | $-3.91M ▲ | -66.92% ▲ | $-0.36 ▲ | $-3.49M ▲ |
| Q3-2024 | $4.36M | $5.76M | $-10.28M | -236.1% | $-0.98 | $-4.72M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $59.09M ▲ | $94.42M ▲ | $34.98M ▼ | $50.16M ▲ |
| Q2-2025 | $32.44M ▼ | $67M ▼ | $46.88M ▲ | $20.12M ▼ |
| Q1-2025 | $38.27M ▲ | $69.02M ▼ | $37.74M ▼ | $31.27M ▲ |
| Q4-2024 | $9.15M ▼ | $73.5M ▼ | $42.34M ▲ | $31.15M ▼ |
| Q3-2024 | $45.56M | $74.73M | $40.5M | $34.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.65M ▲ | $-2.6M ▲ | $3.73M ▼ | $31.93M ▲ | $58.03M ▲ | $-3.7M ▲ |
| Q2-2025 | $-13.32M ▼ | $-5.76M ▼ | $4.91M ▲ | $549K ▲ | $-300K ▲ | $-6.8M ▼ |
| Q1-2025 | $-726K ▲ | $-4.11M ▼ | $-3.34M ▼ | $-362K ▲ | $-7.8M ▼ | $-5.07M ▼ |
| Q4-2024 | $-3.91M ▲ | $-1.64M ▲ | $4.83M ▲ | $-513K ▼ | $2.68M ▼ | $-2.44M ▲ |
| Q3-2024 | $-10.28M | $-3.76M | $-14.29M | $20.71M | $2.69M | $-4.95M |
CEO
Ofer Gonen
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-12-20 | Reverse | 1:7 |
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
INVESTOR AB
Shares:872.09K
Value:$14.86M
YELIN LAPIDOT HOLDINGS MANAGEMENT LTD.
Shares:809.95K
Value:$13.8M
ROSALIND ADVISORS, INC.
Shares:749.05K
Value:$12.76M
Summary
Showing Top 3 of 86